Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2858 + anlotinib
- Development stage
- Phase 2
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**TQB2858 + anlotinib** is an investigational combination therapy currently in clinical development for advanced and recurrent cancers such as endometrial carcinoma. TQB2858 is a bifunctional humanized monoclonal antibody designed to simultaneously block programmed death-ligand 1 (PD-L1) and transforming growth factor beta (TGF-β), aiming to restore antitumor immune responses while inhibiting tumor-promoting effects of TGF-β. Anlotinib is an oral small molecule tyrosine kinase inhibitor (TKI) that targets multiple receptors involved in angiogenesis and tumor growth, most notably vascular endothelial growth factor receptors (VEGFR-1/2/3), fibroblast growth factor receptors (FGFR-1/2/3/4), platelet-derived growth factor receptors (PDGFR-α/β), and c-Kit. The combination is being evaluated for potential synergistic immunotherapy and antiangiogenic effects in advanced malignancies, and is under clinical investigation by Chia Tai Tianqing Pharmaceutical Group.
- Other names
- TQB2858TQB-2858TQB 2858anlotinib hydrochloride
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)CD274 (Programmed cell death protein 1 ligand 1)TGFB (GARP–latent transforming growth factor beta 1 complex)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on TQB2858 + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2858 + anlotinib.